The trial is called DART (Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors) and is managed by SWOG, the cancer clinical trials group that is part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN).
It is in conjunction with the NCI – MATCH program. Patients not having treatment options under MATCH, or if they didn’t respond to treatment on that trial, and their cancer is eligible, they can enroll.
https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match
DART patients will be treated with two immunotherapy drugs—ipilimumab plus nivolumab—a combination treatment that helps the immune system fight cancer.
Hugs
Marion